Your browser doesn't support javascript.
loading
Early cross-coronavirus reactive signatures of protective humoral immunity against COVID-19.
Kaplonek, Paulina; Wang, Chuangqi; Bartsch, Yannic; Fischinger, Stephanie; Gorman, Matthew J; Bowman, Kathryn; Kang, Jaewon; Dayal, Diana; Martin, Patrick; Nowak, Radoslaw; Hsieh, Ching-Lin; Feldman, Jared; Julg, Boris; Nilles, Eric J; Musk, Elon R; Menon, Anil S; Fischer, Eric S; McLellan, Jason S; Schmidt, Aaron; Goldberg, Marcia B; Filbin, Michael; Hacohen, Nir; Lauffenburger, Douglas A; Alter, Galit.
Afiliação
  • Kaplonek P; Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA.
  • Wang C; Department of Biological Engineering, Massachusetts Institute of Technology, MA, USA.
  • Bartsch Y; Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA.
  • Fischinger S; Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA.
  • Gorman MJ; Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA.
  • Bowman K; Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA.
  • Kang J; Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA.
  • Dayal D; Space Exploration Technologies Corp, USA.
  • Martin P; Space Exploration Technologies Corp, USA.
  • Nowak R; Massachusetts General Hospital, USA.
  • Hsieh CL; Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA.
  • Feldman J; Department of Biological Engineering, Massachusetts Institute of Technology, MA, USA.
  • Julg B; Space Exploration Technologies Corp, USA.
  • Nilles EJ; Brigham Women's Hospital, USA.
  • Musk ER; Massachusetts General Hospital, USA.
  • Menon AS; Broad Institute, USA.
  • Fischer ES; Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA.
  • McLellan JS; Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA.
  • Schmidt A; Brigham Women's Hospital, USA.
  • Goldberg MB; Space Exploration Technologies Corp, USA.
  • Filbin M; Space Exploration Technologies Corp, USA.
  • Hacohen N; Massachusetts General Hospital, USA.
  • Lauffenburger DA; Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA.
  • Alter G; Department of Biological Engineering, Massachusetts Institute of Technology, MA, USA.
bioRxiv ; 2021 May 12.
Article em En | MEDLINE | ID: mdl-34013263
ABSTRACT
The introduction of vaccines has inspired new hope in the battle against SARS-CoV-2. However, the emergence of viral variants, in the absence of potent antivirals, has left the world struggling with the uncertain nature of this disease. Antibodies currently represent the strongest correlate of immunity against COVID-19, thus we profiled the earliest humoral signatures in a large cohort of severe and asymptomatic COVID-19 individuals. While a SARS-CoV-2-specific immune response evolved rapidly in survivors of COVID-19, non-survivors exhibited blunted and delayed humoral immune evolution, particularly with respect to S2-specific antibody evolution. Given the conservation of S2 across ß-coronaviruses, we found the early development of SARS-CoV-2-specific immunity occurred in tandem with pre-existing common ß-coronavirus OC43 humoral immunity in survivors, which was selectively also expanded in individuals that develop paucisymptomatic infection. These data point to the importance of cross-coronavirus immunity as a correlate of protection against COVID-19.
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2021 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2021 Tipo de documento: Article